<p>The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile</p>Nicola Squillace, Paolo Bonfanti, Elena Ricci et al.|Drug Design Development and Therapy|2020Cited by 36
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational StudyLucia Taramasso, Giuliana Guadagnino, Giovanni Cenderello et al.|AIDS Patient Care and STDs|2021Cited by 25
<p>Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort</p>Paolo Bonfanti, Giordano Madeddu, Andrea De Vito et al.|Infection and Drug Resistance|2020Cited by 14
Abstract Supplement HIV Glasgow 10–13 November 2024, Glasgow, UK/VirtualL Taramasso, Paolo Bonfanti, Nicola Squillace et al.|Journal of the International AIDS Society|2024Cited by 13
Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA StudyPaolo Bonfanti, Barbara Menzaghi, Giancarlo Orofino et al.|Viruses|2024Cited by 13